#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	22800	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2092	1079.6	0	.	n	.	0	A800G	SNP	800	800	A	1027	1027	G	1295	G,A	674,578	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	22800	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2092	1079.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1677	1677	T	1316	T,C	1220,12	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	22800	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2092	1079.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1411	1411	C	1314	C,T	1269,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	41546	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3495	1180.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1686	1686	A	1378	A,G,T	1321,12,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	41546	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3495	1180.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2320	2320	C	1321	C,G	1283,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	41546	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3495	1180.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2394	2394	A	1351	A	1316	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	41546	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3495	1180.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2946	2946	C	1252	C	1214	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	41546	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3495	1180.8	0	HET	.	.	.	C1644T	.	1644	1644	C	1993	1993	C	1274	C,T	956,278	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	3080	folP	855	855	100.0	folP.l15.c4.ctg.1	1471	208.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1003	1005	AGC	318;315;317	A;G;C	308;303;301	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	8670	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3293	261.6	1	SNP	p	S91F	1	.	.	271	273	TTC	496	498	TTC	318;317;318	T;T;C	305;305;306	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	8670	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3293	261.6	1	SNP	p	G95N	0	.	.	283	285	GGC	508	510	GGC	316;312;308	G;G;C	299;296;296	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	8670	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3293	261.6	1	SNP	p	D95G	1	.	.	283	285	GGC	508	510	GGC	316;312;308	G;G;C	299;296;296	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	2710	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1363	197.7	1	SNP	p	G45D	0	.	.	133	135	GGC	540	542	GGC	333;332;331	G;G;C	318;320;321	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1330	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1006	131.6	0	.	n	.	0	A197.	DEL	197	197	A	595	595	A	309	A	302	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	7594	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2825	266.6	0	.	p	.	0	G85D	NONSYN	253	255	GGC	525	527	GAC	303;296;300	G;A,G;C	300;282,4;295	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	7594	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2825	266.6	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1422	1424	GTC	309;306;303	G;T,G;C,T,A	295;290,1;291,1,1	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	7594	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2825	266.6	1	SNP	p	D86N	0	.	.	256	258	GAC	528	530	GAC	297;295;299	G;A;C	291;278;294	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	7594	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2825	266.6	1	SNP	p	R87I	0	.	.	259	261	CGT	531	533	CGT	300;300;299	C;G;T	293;293;290	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	7594	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2825	266.6	1	SNP	p	S87R	1	.	.	259	261	CGT	531	533	CGT	300;300;299	C;G;T	293;293;290	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	7594	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2825	266.6	1	SNP	p	R87W	0	.	.	259	261	CGT	531	533	CGT	300;300;299	C;G;T	293;293;290	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	7594	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2825	266.6	1	SNP	p	S88P	0	.	.	262	264	TCC	534	536	TCC	296;300;302	T;C;C	285;290;296	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	6510	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2550	253.6	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1287	1289	TGC	266;263;265	T,C;G,T;C,T	255,1;255,1;255,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	6510	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2550	253.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1497	1499	GGC	348;342;343	G;G;C	338;328;324	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	6230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2324	265.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1296	1298	GCA	351;355;355	G;C;A,C	334;334;339,1	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	6230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2324	265.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1299	1301	ATC	359;359;361	A;T;C	341;343;342	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	6230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2324	265.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1311	1313	GTG	355;355;356	G;T;G	346;340;345	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	6230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2324	265.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1311	1313	GTG	355;355;356	G;T;G	346;340;345	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	6230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2324	265.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1815	1817	ACC	300;301;304	A;C;C	284;293;294	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	6230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2324	265.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1869	1871	GCG	271;271;272	G;C,T,G;G	254;229,1,1;255	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	6230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2324	265.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1869	1871	GCG	271;271;272	G;C,T,G;G	254;229,1,1;255	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	6230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2324	265.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1992	1994	GGC	231;233;229	G,A;G;C	220,2;221;216	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	6230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2324	265.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2001	2003	GGC	228;223;223	G;G;C	213;215;209	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	6230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2324	265.2	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2019	2021	TCG	223;223;222	T,G,C;C,G;G,C	153,23,3;189,2;193,3	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	8876	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3036	290.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1662	1664	CCG	293;294;294	C;C,A;G	271;281,2;278	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3934	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1767	220.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	581	581	C	278	C	260	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4294	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1523	279.8	0	.	p	.	0	N38E	NONSYN	112	114	AAT	443	445	GAA	356;361;361	G;A;A	344;344;349	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4294	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1523	279.8	0	.	p	.	0	N134D	NONSYN	400	402	AAT	731	733	GAT	350;353;358	G,T;A;T	334,1;336;340	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4294	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1523	279.8	0	.	p	.	0	P175S	NONSYN	523	525	CCA	854	856	TCA	336;337;334	T;C;A	324;323;323	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4294	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1523	279.8	0	.	p	.	0	A218V	NONSYN	652	654	GCC	983	985	GTC	366;360;358	G,A;T,C;C	352,1;344,1;345	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4294	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1523	279.8	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1313	1315	GCA	339;337;339	G;C,A;A	326;329,1;329	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4294	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1523	279.8	1	SNP	p	G120K	1	.	.	358	360	AAG	689	691	AAG	328;328;328	A;A;G	319;322;319	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4294	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1523	279.8	1	SNP	p	D121N	0	.	.	361	363	GAC	692	694	GAC	329;326;329	G,A;A;C	318,1;316;320	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4294	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1523	279.8	1	SNP	p	A121D	1	.	.	361	363	GAC	692	694	GAC	329;326;329	G,A;A;C	318,1;316;320	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	15390	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	4930	310.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2101	2103	AAT	293;293;299	A,C;A;T	281,2;285;289	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1776	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1085	162.7	1	SNP	p	V57M	1	.	.	169	171	ATG	586	588	ATG	371;375;378	A,G;T;G	366,1;371;371	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
